Acelyrin (SLRN) reported a Q3 net loss late Wednesday of $0.49 per diluted share, narrowing from a loss of $0.87 a year earlier.
Analysts polled by Capital IQ expected loss of $0.81.
Cash, cash equivalents and short-term marketable securities as of Sept. 30 were $562.4 million, according to the company.
Acelyrin said it expects these to fund operations to mid-2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments